» Articles » PMID: 21061761

Dendritic Cells and T Cells in Immunotherapy

Overview
Specialty Dermatology
Date 2010 Nov 11
PMID 21061761
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Autologous cellular immunotherapies have been used experimentally in humans to treat many types of cancer. These therapies are divided into two principal types: active cellular immunotherapies that rely on autologous dendritic cells or other antigen presenting cells; and adoptive T-cell therapies, in which large numbers of antigen-specific T lymphocytes are propagated ex vivo and then infused back into the patient. With the FDA approval of the antigen presenting cell vaccine sipuleucel-T for prostate cancer, active immunization has become an accepted approach for the treatment of established cancer.

Citing Articles

Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Chesson C, Zloza A Nanomedicine (Lond). 2017; 12(23):2693-2706.

PMID: 29098928 PMC: 5704090. DOI: 10.2217/nnm-2017-0254.


Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Henry J, Labarthe M, Meyer B, Dasgupta P, Dalgleish A, Galustian C Immunology. 2013; 139(3):377-85.

PMID: 23374145 PMC: 3701184. DOI: 10.1111/imm.12087.


Effects of 4-1BB signaling on the biological function of murine dendritic cells.

Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Chen H Oncol Lett. 2012; 3(2):477-481.

PMID: 22740935 PMC: 3362585. DOI: 10.3892/ol.2011.506.